Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 2/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30368129 | 0.80 | GSK3B (0.48) | GSK3BHTR6PDE10A | |
| SCHEMBL13093644 | 0.78 | PDE10A (0.40) | GSK3BADRA1AHTR2BPDE10A | |
| SCHEMBL18997546 | 0.77 | GSK3B (0.42) | GSK3B | |
| SCHEMBL10349658 | 0.77 | GSK3B (0.46) | GSK3BCCR2 | |
| Hydrochloric Acid SCHEMBL10382897 | 0.75 | GSK3B (0.45) | GSK3BCCR2HTR2AHTR2CHTR2B | |
| SCHEMBL27948360 | 0.75 | GSK3B (0.44) | GSK3BHTR6TP53HTR2AHTR2C | |
| SCHEMBL19049080 | 0.74 | GSK3B (0.44) | GSK3B | |
| SCHEMBL25224837 | 0.74 | MAPK1 (0.46) | GSK3B | |
| SCHEMBL31449823 | 0.73 | GSK3B (0.39) | GSK3BHTR6 | |
| SCHEMBL21776340 | 0.73 | RIPK1 (0.42) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072451-A1 | RAS-PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOLOGICAL DISEASES | VIVIDION THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |